Impaired Hepatic Function Clinical Trial
Official title:
A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.
This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04136444 -
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT02135302 -
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02388620 -
Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011
|
Phase 1 | |
| Completed |
NCT01950481 -
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT00398424 -
Evaluating Patients With Impaired Hepatic Function
|
Phase 1 | |
| Recruiting |
NCT05259085 -
Study of ALXN2050 in Participants With Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT04823702 -
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
|
Phase 1 |